Therapeutic Platform
Immuno-Oncology Research Services
Accelerating Cancer Immunotherapy Development with Advanced Immuno-Oncology Research Services
Developing successful cancer immunotherapies requires more than traditional laboratory testing. Today’s oncology innovators need a deeper understanding of how therapies interact with the immune system, activate anti-tumor responses, and deliver meaningful clinical outcomes.
At ImmunitasBio, we provide comprehensive Immuno-Oncology Research Services that help biotechnology companies, pharmaceutical organizations, and therapeutic developers accelerate Immuno-Oncology Drug Development through scientifically robust, mechanism-driven evaluation strategies.
Our integrated Cancer Immunotherapy Research Services platform generates actionable biological insights that enable sponsors to identify promising therapeutic candidates, reduce development risk, and advance programs with greater confidence.
Whether you are developing Monoclonal Antibodies, Antibody Drug Conjugates (ADCs), Bispecific Antibodies, Peptide Therapeutics, or Next-Generation Cancer Biologics, our team delivers the functional data needed to support critical development decisions.
Why Are Immuno-Oncology Research Services Critical for Cancer Drug Development?
Cancer therapies are increasingly designed to harness the body’s immune system. However, many promising candidates fail because developers lack a complete understanding of immune activation, anti-tumor activity, and therapeutic mechanisms.
Successful Immuno-Oncology Drug Development requires answers to critical questions:
Our Cancer Immunotherapy Testing Services help answer these questions early in development, enabling better candidate selection and stronger regulatory strategies.
Our Integrated Immunotherapy Evaluation Platform
As a trusted partner for Preclinical Immuno-Oncology Services, ImmunitasBio combines advanced biology, translational research expertise, and clinically relevant testing models to support the complete immunotherapy development lifecycle.
Our Immunotherapy Evaluation Platform provides:
The result is a comprehensive biological understanding of your therapeutic candidate before clinical development begins.
Monoclonal Antibody Development Services
Monoclonal antibodies continue to play a central role in cancer treatment and immune-based therapeutics.
Our Monoclonal Antibody Development Services help sponsors characterize biological activity and therapeutic potential through:
These studies provide the evidence needed to advance the most promising antibody candidates.
Antibody Drug Conjugate (ADC) Research Services
ADCs combine the specificity of antibodies with the potency of targeted payloads, making them one of the fastest-growing therapeutic modalities in oncology.
Our Antibody Drug Conjugate (ADC) Research Services support every stage of ADC evaluation, including:
Our goal is to help sponsors understand how ADCs perform in biologically relevant systems before advancing into clinical development.
Functional Immune Profiling and Tumor Cell Killing Assays
Understanding how a therapy affects immune function is essential for successful oncology development.
Our Functional Immune Profiling Services measure:
Using advanced Tumor Cell Killing Assays, we evaluate the ability of therapeutic candidates to eliminate cancer cells under biologically relevant conditions.
These insights help predict therapeutic performance and improve development decisions.
Bispecific Antibody Development and Evaluation
Bispecific antibodies represent a new generation of cancer immunotherapies designed to redirect immune cells toward tumor targets.
Our Antibody Drug Conjugate (ADC) Research Services support every stage of ADC evaluation, including:
Mechanism of Action Studies and Translational Immuno-Oncology Research
One of the most important aspects of successful Cancer Biologics Development is understanding how therapies work.
Our Mechanism of Action Studies help developers:
Through Translational Immuno-Oncology Research, we generate clinically relevant data that bridges preclinical findings and clinical outcomes.
Why Partner with ImmunitasBio for Immuno-Oncology Research?
Unlike conventional testing providers, ImmunitasBio functions as a strategic scientific partner.
As an emerging Immuno-Oncology CRO in India, we help organizations accelerate oncology innovation through:
Our mission is simple: help innovators develop safer, more effective cancer therapies and bring them to patients faster.
Bispecific Antibody Development and Evaluation
Bispecific antibodies represent a new generation of cancer immunotherapies designed to redirect immune cells toward tumor targets.
Our Bispecific Antibody Development platform supports:
These studies provide critical insights into therapeutic efficacy and immune engagement.
